Literature DB >> 11300476

Expression of CD56 by human papillomavirus E7-specific CD8+ cytotoxic T lymphocytes correlates with increased intracellular perforin expression and enhanced cytotoxicity against HLA-A2-matched cervical tumor cells.

A D Santin1, P L Hermonat, A Ravaggi, S Bellone, J J Roman, S Jayaprabhu, S Pecorelli, G P Parham, M J Cannon.   

Abstract

Human papillomavirus (HPV) infection represents the most important risk factor for developing cervical cancer. In this study, we examine the potential of full-length E7-pulsed autologous dendritic cells (DCs) to induce antigen-specific CTL responses from the peripheral blood of healthy individuals against HLA-A2-matched HPV-16 and HPV-18-positive tumor target cells in vitro. We show that DCs pulsed with E7 oncoprotein can consistently stimulate antigen-specific CTL responses that recognize and lyse HPV-16 or HPV-18-positive naturally infected cervical cancer cell lines. HPV-negative, EBV-transformed lymphoblastoid cell lines (LCLs) sharing the HLA haplotype of the target tumor cells, as well as autologous donor LCLs, were not significantly killed by E7-specific CTLs. Cytotoxicity against HLA-A2-matched HPV-16 and HPV-18 tumor target cells could be significantly inhibited by anti-HLA class I and by anti-HLA-A2 monoclonal antibodies. CD8+ CTLs expressed variable levels of CD56 and showed a strongly polarized Type 1 cytokine profile. Sorting of the CD8+ T cells on the basis of CD56 expression demonstrated that the most highly cytotoxic CTLs were CD56+ and expressed higher levels of perforin and IFN-gamma, compared with the CD8+/CD56- population. Taken together, these data demonstrate that full-length, E7-pulsed DCs can consistently induce E7-specific CD8+ CTL responses in healthy individuals that are able to kill naturally HPV-16 and HPV-18-infected cancer cells, and that CD56 expression defines a subset of CD8+ CTLs with high cytolytic activity against tumor cells.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11300476

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  11 in total

1.  Increased numbers and functional activity of CD56⁺ T cells in healthy cytomegalovirus positive subjects.

Authors:  Mazen Almehmadi; Brian F Flanagan; Naeem Khan; Suliman Alomar; Stephen E Christmas
Journal:  Immunology       Date:  2014-06       Impact factor: 7.397

2.  Antigen-driven T-cell selection in patients with cervical cancer as evidenced by T-cell receptor analysis and recognition of autologous tumor.

Authors:  H Pilch; H Höhn; C Neukirch; K Freitag; P G Knapstein; B Tanner; M J Maeurer
Journal:  Clin Diagn Lab Immunol       Date:  2002-03

3.  Regulation of HLA-DR and co-stimulatory molecule expression on natural killer T cells by granulocyte-macrophage colony-stimulating factor.

Authors:  Kamal U Saikh; Teri Kissner; Robert G Ulrich
Journal:  Immunology       Date:  2002-07       Impact factor: 7.397

4.  Human papillomavirus type 16 (HPV-16) virus-like particle L1-specific CD8+ cytotoxic T lymphocytes (CTLs) are equally effective as E7-specific CD8+ CTLs in killing autologous HPV-16-positive tumor cells in cervical cancer patients: implications for L1 dendritic cell-based therapeutic vaccines.

Authors:  Stefania Bellone; Karim El-Sahwi; Emiliano Cocco; Francesca Casagrande; Marilisa Cargnelutti; Michela Palmieri; Eliana Bignotti; Chiara Romani; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Alessandro D Santin
Journal:  J Virol       Date:  2009-04-22       Impact factor: 5.103

5.  Definition of the HLA-A2 restricted peptides recognized by human CD8+ effector T cells by flow-assisted sorting of the CD8+ CD45RA+ CD28- T cell subpopulation.

Authors:  H Höhn; M Jülch; H Pilch; C Kortsik; G Tully; C Neukirch; K Freitag; M Maeurer
Journal:  Clin Exp Immunol       Date:  2003-01       Impact factor: 4.330

6.  Human papillomavirus type 16 and 18 E7-pulsed dendritic cell vaccination of stage IB or IIA cervical cancer patients: a phase I escalating-dose trial.

Authors:  Alessandro D Santin; Stefania Bellone; Michela Palmieri; Alessandro Zanolini; Antonella Ravaggi; Eric R Siegel; Juan J Roman; Sergio Pecorelli; Martin J Cannon
Journal:  J Virol       Date:  2007-12-05       Impact factor: 5.103

7.  Dendritic cell-based tumor vaccine for cervical cancer I: in vitro stimulation with recombinant protein-pulsed dendritic cells induces specific T cells to HPV16 E7 or HPV18 E7.

Authors:  Marion Nonn; Manuela Schinz; Klaus Zumbach; Michael Pawlita; Achim Schneider; Matthias Dürst; Andreas M Kaufmann
Journal:  J Cancer Res Clin Oncol       Date:  2003-08-02       Impact factor: 4.553

8.  Mammaglobin B (SCGB2A1) is a novel tumour antigen highly differentially expressed in all major histological types of ovarian cancer: implications for ovarian cancer immunotherapy.

Authors:  S Bellone; R Tassi; M Betti; D English; E Cocco; S Gasparrini; I Bortolomai; J D Black; P Todeschini; C Romani; A Ravaggi; E Bignotti; E Bandiera; L Zanotti; S Pecorelli; L Ardighieri; M Falchetti; C Donzelli; E R Siegel; M Azodi; D-A Silasi; E Ratner; P E Schwartz; T J Rutherford; A D Santin
Journal:  Br J Cancer       Date:  2013-06-27       Impact factor: 7.640

9.  Interleukin-15-induced CD56(+) myeloid dendritic cells combine potent tumor antigen presentation with direct tumoricidal potential.

Authors:  Sébastien Anguille; Eva Lion; Jurjen Tel; I Jolanda M de Vries; Karen Couderé; Phillip D Fromm; Viggo F Van Tendeloo; Evelien L Smits; Zwi N Berneman
Journal:  PLoS One       Date:  2012-12-28       Impact factor: 3.240

10.  Granzyme B mediated function of Parvovirus B19-specific CD4(+) T cells.

Authors:  Arun Kumar; Maria F Perdomo; Anu Kantele; Lea Hedman; Klaus Hedman; Rauli Franssila
Journal:  Clin Transl Immunology       Date:  2015-07-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.